Vaxxinity, Inc. (VAXX) News
Filter VAXX News Items
VAXX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VAXX News Highlights
- VAXX's 30 day story count now stands at 2.
- Over the past 22 days, the trend for VAXX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AC and TOP are the most mentioned tickers in articles about VAXX.
Latest VAXX News From Around the Web
Below are the latest news stories about VAXXINITY INC that investors may wish to consider to help them evaluate VAXX as an investment opportunity.
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityBiogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. |
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successBreakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. |
Vaxxinity to Present at Upcoming November Medical and Investor ConferencesCAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi |
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateCAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have |
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineKey Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a... |
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Vaxxinity to Present at Upcoming Investor Conferences in SeptemberCAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September: H.C. Wainwright 25th Annual Global Investment ConferenceDate: Monday, September 11, 2023Time: 5:00 – 5:30 p.m. (ET)Format: Corporate Presentation A live webcast of t |
Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s TreatmentBy Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said early clinical data demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease for its UB-311 vaccine. The Phase 2a study, conducted in Taiwan showed that UB-311 offers advantages such as lower ARIA-E rates, convenient dosing via intramuscular injection, and cost-effectiveness, the company said in a statement. Co-author […] |
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseasePhase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E CAPE CANAVERAL, Fla., Aug. 10, 2023 (GLOBE NEWSW |
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateCAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “Vaxxinity has broken new ground in the first half of 2023. Now in three independent programs, UB-311, UB-312, and UB-313, we have demonstrated proof of technology and our ability to safely induce antibodies in subjects through act |